| __timestamp | AstraZeneca PLC | Catalent, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5842000000 | 1229100000 |
| Thursday, January 1, 2015 | 4646000000 | 1215500000 |
| Friday, January 1, 2016 | 4126000000 | 1260500000 |
| Sunday, January 1, 2017 | 4318000000 | 1420800000 |
| Monday, January 1, 2018 | 4936000000 | 1710800000 |
| Tuesday, January 1, 2019 | 4921000000 | 1712900000 |
| Wednesday, January 1, 2020 | 5299000000 | 2111000000 |
| Friday, January 1, 2021 | 12437000000 | 2646000000 |
| Saturday, January 1, 2022 | 12391000000 | 3188000000 |
| Sunday, January 1, 2023 | 8040000000 | 3216000000 |
| Monday, January 1, 2024 | 10207000000 | 3428000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. AstraZeneca PLC and Catalent, Inc. have shown distinct trends in their cost of revenue from 2014 to 2023. AstraZeneca's costs peaked in 2021, reaching nearly double their 2014 levels, before dropping by 35% in 2023. Meanwhile, Catalent's costs have steadily increased, with a notable 160% rise over the same period. This divergence highlights AstraZeneca's fluctuating expenses, possibly due to strategic shifts or market conditions, while Catalent's consistent growth suggests a stable expansion strategy. The absence of data for AstraZeneca in 2024 leaves room for speculation on future trends. As these companies navigate the complexities of the pharmaceutical industry, their cost management strategies will be pivotal in maintaining competitive advantage.
Cost of Revenue Comparison: Eli Lilly and Company vs Catalent, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Takeda Pharmaceutical Company Limited's Expenses
Cost Insights: Breaking Down AstraZeneca PLC and Regeneron Pharmaceuticals, Inc.'s Expenses
AstraZeneca PLC vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for AstraZeneca PLC and Veracyte, Inc.
Comparing Cost of Revenue Efficiency: AstraZeneca PLC vs Bausch Health Companies Inc.
Analyzing Cost of Revenue: AstraZeneca PLC and Galapagos NV
Analyzing Cost of Revenue: Zoetis Inc. and Catalent, Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Catalent, Inc.
Catalent, Inc. vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Catalent, Inc. and Alkermes plc's Expenses
Cost Insights: Breaking Down Catalent, Inc. and PTC Therapeutics, Inc.'s Expenses